Couple organ transplants with 3D printing and you get bio-printing — the prospect of 3D printers building human organs. Blood vessels and even a functional ear have already been printed. But can a lab-created organ be patented, when it replicates a natural organ using natural cells?
The technology
3D printing dates to the 1980s; bio-printing applies it to synthetically create human organs. Scientists and biotech companies are racing to make 3D-printed organs for transplants, research and drug testing. The prize: organs printed from a patient’s own cells, eliminating the immune rejection that plagues transplants.
If realised, it would be a medical revolution — and inevitably a rush to patent so rewarding a technology.
The patent puzzle
As with gene patents, the biotechnology–patent interplay is blurry, left to courts and patent offices. Both India and the US discourage patenting “a naturally occurring” element, and uncertainty surrounds whether a synthetically altered version of a natural specimen is patent-eligible.
The exception: human manufacture, not nature
Following Myriad (applied by the Indian Patent Office in recent cases), the obvious argument for patentability is that a bio-printed organ is not a product occurring in nature, but a product of human manufacture and innovation. The sophisticated scientific methods and precise machinery needed to compose and manufacture a 3D-printed organ bolster the claim that it’s a synthesised product, not found in nature.
The dilemma
But the Patent Office (or courts) may struggle to overlook a genuine fact: these organs merely replicate the design, shape and functions of a naturally occurring human organ — and are built using real human cells (occurring in nature) as building blocks. That tension — man-made process versus nature-replicating output built from natural material — is where Section 3(c) and the “product of nature” logic collide.
As Margaret Drabble put it: “When nothing is sure, everything is possible.” For now, the fate of a lab-created human organ under patent law remains open.
The takeaways
- Bio-printing may make transplantable organs from a patient’s own cells.
- Natural elements aren’t patentable — in India (Section 3(c)) or the US.
- The pro-patent argument: a bio-printed organ is human manufacture, not a product of nature.
- The dilemma: it replicates a natural organ from natural cells — an unsettled question.
Frequently asked questions
Can a 3D-printed human organ be patented in India? It’s unsettled — the pro-patent argument is that it’s a product of human manufacture (not nature), but it replicates a natural organ from natural cells, which may engage the Section 3(c) bar.
Why might a bio-printed organ be patentable? Because, following Myriad, a product whose form is dictated by human innovation (not nature) can be patent-eligible — and bio-printing involves sophisticated methods and machinery.
What’s the argument against patentability? That the organ merely replicates the design, shape and function of a naturally occurring organ, using real human cells as building blocks.
Does India patent naturally occurring biological material? No — Section 3(c) bars patents on living things or substances occurring in nature; the question is whether a synthetically manufactured organ escapes that bar.
Useful official resources
- The Patents Act, 1970
- Indian Patent Office — patents